NASDAQ: MDCXMedicus Pharma Ltd Stock
$0.32+0.00 (+0%)
Updated Jun 10, 2026
MDCX Price
$0.32
Fair Value Price
$0.27
Market Cap
$18.13M
52 Week Low
$0.25
52 Week High
$3.69
P/E
-0.12x
P/B
13.67x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$39.38M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
4.52
Operating Cash Flow
-$28M
Beta
1.01
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MDCX Overview
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MDCX's potential to beat the market
- MDCX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
MDCX
RankedUnranked of 16
RankedUnranked of 16
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $1,136.37 | A | |
| $178.96 | B | |
| $55.60 | B |
Be the first to know about important MDCX news, forecast changes, insider trades & much more!
MDCX News
Overview
Due Diligence Score
–
Industry Average (37)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MDCX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MDCX ($0.32) is overvalued by 17.44% relative to our estimate of its Fair Value price of $0.27 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MDCX ($0.32) is not significantly undervalued (17.44%) relative to our estimate of its Fair Value price of $0.27 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MDCX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MDCX due diligence checks available for Premium users.
Valuation
MDCX fair value
Fair Value of MDCX stock based on Discounted Cash Flow (DCF)
Price
$0.32
Fair Value
$0.27
Overvalued by
17.44%
MDCX ($0.32) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MDCX ($0.32) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MDCX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MDCX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
37.65x
Market
14.77x
MDCX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
13.67x
Industry
7.24x
MDCX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MDCX's financial health
Profit margin
Revenue
$0.0
Net Income
-$9.0M
Profit Margin
0%
MDCX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$7.4M
Liabilities
$6.0M
Debt to equity
4.52
MDCX's short-term assets ($7.28M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MDCX's short-term assets ($7.28M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MDCX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.0M
Investing
$0.0
Financing
$6.8M
MDCX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MDCX vs General Drug Manufacturer Stocks
Medicus Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.